Winston Wong, PharmD, Editor-in-Chief, discusses the features in this issue, which cover new technology that may help guide treatment decisions for patients with metastatic breast cancer and differences in referral patterns and treatment...
Winston Wong, PharmD, Editor-in-Chief, discusses the features in this issue, which cover new technology that may help guide treatment decisions for patients with metastatic breast cancer and differences in referral patterns and treatment...
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.
Richard G. Stefanacci, DO, MGH, MBA, AGSF, CMD, discusses the drug benefits provided under each of the current Medicare Parts and the future of Medicare design.
The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.
The Association of Community Cancer Centers developed an innovative learning tool that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain MRD testing for adult patients with ALL.
Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.
Cynthia Miller, MD, MPH, FACP, discusses initiatives pharmaceutical companies can employ to assist physician groups and payers in adding appropriate pharmacologic therapies to reduce the burden of COVID-19 on persons with diabetes.
Rajiv Panikkar, MD, explains how embedding clinical trials into the oncology pathways at Geisinger’s Cancer Institute has increased awareness of their clinical research program.
Rajiv Panikkar, MD, explains how embedding clinical trials into the oncology pathways at Geisinger’s Cancer Institute has increased awareness of their clinical research program.
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Poorni M. Manohar, MD, et al assessed the potential value of 18-F 16 alpha-fluoroestradiol positron emission tomography (FES-PET) vs biopsy to determine estrogen receptor status and guide therapy selection in metastatic breast cancer.
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Ajeet Gajra, MD, FACP, et al assessed the differences between medical oncologists and urologists regarding perceptions on timing of referral and treatment sequence decisions for patients with advanced prostate cancer
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.
NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.